S1 Fig. Rate of incident MACE per 100 patient years by average achieved on-treatment LDL-D levels in patients with ASCVD with and without comorbidities in a pooled analysis of alirocumab Phase 3a trials using a multivariate Poisson analysis adjusted for baseline characteristics
From: Vallejo-Vaz AJ, Ray KK, Ginsberg HN, et al. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab. Atherosclerosis. 2019;288:85-93.

CKD	Chronic kidney disease
DM	Diabetes mellitus
MACE	Major adverse cardiovascular events
PoVD	Polyvascular disease